Pipeline dossier

NIH & clinical-trial pipeline signals for REGENERON PHARMACEUTICALS, INC. (REGN)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for REGN, mapped to public ticker REGN (CIK 0000872589). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingREGN35% conf

REGENERON PHARMACEUTICALS, INC. (REGN) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Recent SEC 8-K filings

2026-10-30 — 8-K 2.02,9.01 view ↗
2026-10-06 — 8-K 1.01,2.02,8.01 view ↗
2026-09-30 — 8-K 5.02,9.01 view ↗
2026-07-30 — 8-K 2.02,9.01 view ↗
2026-07-06 — 8-K 2.02 view ↗

JSON API for this entity →